Top 5 Presentations from Last year’s World Orphan Drug Congress Europe

In Market Access, Partnering & Investment by Simon Reid

orphan drugs, rare disease, clinical development, market access, HTA, presentations, SOBI, Segolene Ayme, CSL Behring, Vertex PharmaceuticalsAs the agenda and speaking faculty takes shape for the 4th Annual World Orphan Drug Congress Europe, we wanted to take a look back at some of the leading presentations, debates and discussions that took place at last year’s event.

According to a new 2013 Orphan Drug Industry Report from Evaluate, the worldwide orphan drug market is set to reach $127 billion by 2018. While the interest and ROI is increasing for orphan drugs, the World Orphan Drug Congress Europe continues to tackle the challenges facing the rare disease community in order to facilitate mutually beneficial partnerships and the successful development of orphan products for all rare diseases. This eBook contains 5 of the leading presentations from last year’s congress that cover:
• Successful clinical development and approval of an orphan product
• Overcoming pricing and market access challenges facing orphan drugs
• Understanding the partnership and collaboration landscape amongst rare disease stakeholders
• The payer perspective and importance of orphan drug pricing transparency

Download the Top 5 Presentations for last year’s World Orphan Drug Congress Europe

So you now have had a glimpse at the industry shaping discussions presented by thought leaders at the World Orphan Drug Congress in Geneva. The 2013 agenda focus is now taking shape so here are some of the hot industry topics affecting your business and in place to be debated at this years congress:
• Streamlining clinical development and accelerating regulatory approval process
• Understand adaptive licensing to provide clinical added value and quicker patient access
• Aligning all stakeholder perspectives and engaging in cross-stakeholder collaborations
• How to work with regulatory agencies for protocol assistance and scientific advice
• Demonstrating value of an orphan drug and adopting innovative pricing models
• Harmonise global market access and stakeholder pricing transparency
• How to commercialise your orphan pipeline and debating corporate development strategy
• Health technology assessment to assess the value determine price
• Future considerations: will current trends affect the sustainability of the orphan drug industry?

If you want to get your hands on some more presentations from last year’s meeting, you can download Catherine Berens, Policy Officer at the European Commission presentation on providing uniform access to medicines in Europe. You can freely download Catherine Beren’s presentation slides here